⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NRSN News
NeuroSense Therapeutics Ltd. Ordinary Shares
NeuroSense Announces Pricing of Insider-Led PIPE Financing
prnewswire.com
NRSN
NeuroSense Granted Brazilian Patent Covering PrimeC Composition
prnewswire.com
NRSN
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements
prnewswire.com
NRSNW
NRSN
NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update
prnewswire.com
NRSN
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout
prnewswire.com
NRSN
PrimeC New Data to Be Presented at AD/PD™ 2026 Conference
prnewswire.com
NRSNW
NRSN
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity
prnewswire.com
NRSNW
NRSN
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference
prnewswire.com
NRSNW
NRSN
NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS
prnewswire.com
NRSNW
NRSN
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition
prnewswire.com
NRSN